NurExone signs binding MOU with Made Scientific for exclusive US GMP exosome manufacturing partnership
Reuters2026/08/12 21:03- NurExone Biologic signed a binding MOU with Made Scientific for an exclusive U.S. GMP manufacturing partnership for bone marrow-derived exosomes.
- Made Scientific to handle U.S. manufacturing, aseptic fill-finish, commercial exosome supply to support clinical development.
- Technology transfer to start immediately; first GMP exosome batches targeted for H1 2027.
- MOU contemplates a 5-year term with 5-year renewal options; exclusivity ends if no definitive deal within six months.
- Company dropped its earlier non-binding LOI with BioXtek as it consolidates U.S. GMP manufacturing under Made Scientific.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
